{"id":26236,"date":"2025-11-05T16:37:06","date_gmt":"2025-11-05T09:37:06","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=26236"},"modified":"2025-11-06T10:21:03","modified_gmt":"2025-11-06T03:21:03","slug":"nicergoline","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/nicergoline\/","title":{"rendered":"Nicergoline"},"content":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

Action and use <\/strong><\/p>\n

Ergot derivative.<\/p>\n

Ph Eur<\/p>\n

\n
DEFINITION<\/h2>\n[(6aR,9R,10aS)-10a-Methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 \u00a05-bromopyridine-3-carboxylate.<\/p>\n
Content<\/strong><\/p>\n
99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
Fine to granular, white or yellowish powder.<\/p>\n
Solubility<\/h3>\n
Practically insoluble in water, freely soluble in methylene chloride, soluble in ethanol (96 per cent).<\/p>\n
It shows polymorphism (5.9).<\/p>\n
IDENTIFICATION<\/h2>\n
First identification: A, C.<\/p>\n
Second identification: A, B, D.<\/p>\n
A. Specific optical rotation (2.2.7): + 4.8 to + 5.8 (anhydrous substance).<\/p>\n
Dissolve 0.50 g in ethanol (96 per cent) R and dilute to 10.0 mL with the same solvent.<\/p>\n
B. Ultraviolet and visible absorption spectrophotometry (2.2.25).<\/p>\n
Test solution\u00a0 Dissolve 50.0 mg in ethanol (96 per cent) R and dilute to 100.0 mL with the same solvent. Dilute 5.0 mL of the solution to 50.0 mL with ethanol (96 per cent) R.<\/p>\n
Spectral range 220-350 nm. Absorption maximum At 288 nm. Absorption minimum At 251 nm.<\/p>\n
Specific absorbance at the absorption maximum\u00a0 175 to 185 (anhydrous substance).<\/p>\n
C. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison\u00a0 nicergoline CRS.<\/p>\n
If the spectra obtained show differences, dissolve the substance to be examined and the reference substance separately in ethanol (96 per cent) R, evaporate to dryness and record new spectra using the residues.<\/p>\n
D. Dissolve 2 mg in 2 mL of sulfuric acid R. A blue colour develops.<\/p>\n
TESTS<\/h2>\n
Appearance of solution<\/h3>\n
The solution is not more opalescent than reference suspension II (2.2.1) and not more intensely coloured than intensity 5 of the range of reference solutions of the most appropriate colour (2.2.2, Method II).<\/p>\n
Dissolve 0.5 g in ethanol (96 per cent) R and dilute to 10 mL with the same solvent.<\/p>\n
Related substances<\/h3>\n
Liquid chromatography (2.2.29).<\/p>\n
Test solution\u00a0 Dissolve 50.0 mg of the substance to be examined in acetonitrile R and dilute to 50.0 mL with the same solvent.<\/p>\n
Reference solution (a)\u00a0 Dilute 1.0 mL of the test solution to 100.0 mL with acetonitrile R. Dilute 2.0 mL of this solution to 10.0 mL with acetonitrile R.<\/p>\n
Reference solution (b)\u00a0 Dissolve 2 mg of nicergoline for system suitability CRS (containing impurities A, B, C, D, F and H) in acetonitrile R and dilute to 2 mL with the same solvent.<\/p>\n
Reference solution (c)\u00a0 Dissolve 5.0 mg of nicergoline impurity D CRS in acetonitrile R and dilute to 100.0 mL with the same solvent. Dilute 2.0 mL of the solution to 50.0 mL with acetonitrile R.<\/p>\n
Reference solution (d)\u00a0 Dissolve the contents of a vial of nicergoline for peak identification CRS (containing impurity I) in 1 mL of acetonitrile R.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n
\u2014 stationary phase: end-capped ethylene-bridged octadecylsilyl silica gel for chromatography (hybrid material) R (3.5 \u00b5m);<\/p>\n
\u2014 temperature: 40 \u00b0C.<\/p>\n
Mobile phase:<\/p>\n
\u2014 solution A: dissolve 34.02 g of potassium dihydrogen phosphate R in 930 mL of water for chromatography R and dilute to 1000 mL with water for chromatography R (buffer solution); dissolve<\/p>\n
21.21 g of tetrabutylammonium hydrogen sulfate R in 225 mL of the buffer solution and dilute to 250.0 mL with the same solution; adjust to pH 7.5 with a 300 g\/L solution of potassium hydroxide R;<\/p>\n
\u2014 mobile phase A: mix 2.0 mL of solution A with 300 mL of acetonitrile R and 700 mL of water for chromatography R;<\/p>\n
\u2014 mobile phase B: mix 2.0 mL of solution A with 300 mL of water for chromatography R and 700 mL of acetonitrile R;<\/p>\n\n\n\n\n\n\n\n
Time (min)<\/strong><\/td>\n Mobile phase A (per cent V\/V)<\/strong><\/td>\n Mobile phase B (per cent V\/V)<\/strong><\/td>\n<\/tr>\n
0 – 3<\/td>\n 100<\/td>\n 0<\/td>\n<\/tr>\n
3 – 30<\/td>\n 100 \u2192 70<\/td>\n 0 \u2192 30<\/td>\n<\/tr>\n
30 – 40<\/td>\n 70 \u2192 0<\/td>\n 30 \u2192 100<\/td>\n<\/tr>\n
40 – 50<\/td>\n 0<\/td>\n 100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Flow rate\u00a0 1.2 mL\/min.<\/p>\n
Detection\u00a0 Spectrophotometer at 288 nm.<\/p>\n
Injection\u00a0 10 \u00b5L.<\/p>\n
Identification of impurities\u00a0 Use the chromatogram supplied with nicergoline for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B, C, F and H; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity I.<\/p>\n
Relative retention\u00a0 With reference to nicergoline (retention time = about 34 min): impurity D = about 0.06; impurity C = about 0.1; impurity B = about 0.6; impurity H = about 0.8; impurity A = about 0.96; impurity F = about 1.1; impurity I = about 1.2.<\/p>\n
System suitability\u00a0 Reference solution (b):<\/p>\n
\u2014 resolution: minimum 2.0 between the peaks due to impurity A and nicergoline.<\/p>\n
Calculation of percentage contents:<\/p>\n
\u2014 for impurity D, use the concentration of impurity D in reference solution (c);<\/p>\n
\u2014 for impurities other than D, use the concentration of nicergoline in reference solution (a).<\/p>\n
Limits:<\/p>\n
\u2014 impurity B: maximum 0.8 per cent;<\/p>\n
\u2014 impurity A: maximum 0.5 per cent;<\/p>\n
\u2014 impurity H: maximum 0.3 per cent;<\/p>\n
\u2014 impurities C, D, F, I: for each impurity, maximum 0.2 per cent;<\/p>\n
\u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n
\u2014 total: maximum 1.2 per cent;<\/p>\n
\u2014 reporting threshold: 0.05 per cent.<\/p>\n
Water (2.5.32)<\/p>\n
Maximum 0.5 per cent, determined on 0.100 g.<\/p>\n
Sulfated ash (2.4.14)<\/p>\n
Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n
ASSAY<\/h2>\n
Dissolve 0.400 g in 50 mL of acetone R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20). Titrate to the 1st point of inflexion.
\n1 mL of 0.1 M perchloric acid is equivalent to 48.44 mg of C_{24<\/sub>H_{26<\/sub>BrN_{3<\/sub>O_{3<\/sub>.<\/p>\n}}}}
IMPURITIES<\/h2>\n
Specified impurities\u00a0 A, B, C, D, F, H, I.<\/em><\/p>\n
Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.<\/em><\/p>\n
Control of impurities in substances for pharmaceutical use)\u00a0 E, G, J.<\/em><\/p>\n
$\"Nicergoline\"$ <\/p>\n
A. [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methyl 5-chloropyridine-3-carboxylate (chloronicergoline),<\/p>\n
$\"Nicergoline\"$ <\/p>\n
B. [(6aR,9R,10aS)-10a-methoxy-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 5-bromopyridine-3-carboxylate (1-desmethylnicergoline),<\/p>\n
$\"Nicergoline\"$ <\/p>\n
C. [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methanol,<\/p>\n
$\"Nicergoline\"$ <\/p>\n
D. 5-bromopyridine-3-carboxylic acid,<\/p>\n
$\"Nicergoline\"$ <\/p>\n
E. [(6aR,9R,10aS)-10a-hydroxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methyl 5-bromopyridine-3-carboxylate,<\/p>\n
$\"Nicergoline\"$ <\/p>\n
F. [(6aR,9S,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methyl 5-bromopyridine-3-carboxylate (isonicergoline),<\/p>\n
$\"Nicergoline\"$ <\/p>\n
G. [(6aR,9R,10aR)-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl 5- bromopyridine-3-carboxylate,<\/p>\n
$\"Nicergoline\"$ <\/p>\n
H. [(6aR,9R,10aS)-10a-methoxy-4-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 5-bromopyridine-3-carboxylate (6-desmethylnicergoline),<\/p>\n
$\"Nicergoline\"$ <\/p>\n
I. [(6aR,6a\u2032R,9R,9\u2032R,10aS,10a\u2032S)-9\u2032-[[[(5-bromopyridin-3-yl)carbonyl]oxy]methyl]-10a,10a\u2032-dimethoxy-7,7\u2032-\u00a0 \u00a0dimethyl-4\u2032,6\u2032,6a,6a\u2032,7,7\u2032,8,8\u2032,9,9\u2032,10,10\u2032,10a,10a\u2032-tetradecahydro-6H-4,5\u2032-biindolo[4,3-fg]quinoline-9-yl]methyl\u00a0 \u00a0 5-bromopyridine-3-carboxylate,<\/p>\n
$\"Nicergoline\"$ <\/p>\n
J. [(6aR,6a\u2032R,9R,9\u2032R,10aS,10a\u2032S)-9\u2032-[[[(5-bromopyridin-3-yl)carbonyl]oxy]methyl]-10a,10a\u2032-dimethoxy- 4\u2032,7,7\u2032-trimethyl-4\u2032,6\u2032,6a,6a\u2032,7,7\u2032,8,8\u2032,9,9\u2032,10,10\u2032,10a,10a\u2032-tetradecahydro-6H-4,5\u2032-biindolo[4,3-fg]quinoline-9-\u00a0 yl]methyl 5-bromopyridine-3-carboxylate.<\/p>\n
\n
Ph Eur<\/p>\n","protected":false},"excerpt":{"rendered":"
Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Ergot derivative. Ph Eur DEFINITION [(6aR,9R,10aS)-10a-Methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 \u00a05-bromopyridine-3-carboxylate. Content 99.0 per cent to 101.0 per cent (anhydrous substance). CHARACTERS Appearance Fine to granular, white or yellowish powder. Solubility Practically insoluble in water, freely soluble in methylene chloride, soluble in ethanol (96 per cent). It shows polymorphism…<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-26236","post","type-post","status-publish","format-standard","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=26236"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26236\/revisions"}],"predecessor-version":[{"id":26799,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26236\/revisions\/26799"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=26236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=26236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=26236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time (min)<\/strong><\/td>\n	Mobile phase A (per cent V\/V)<\/strong><\/td>\n	Mobile phase B (per cent V\/V)<\/strong><\/td>\n<\/tr>\n
0 – 3<\/td>\n	100<\/td>\n	0<\/td>\n<\/tr>\n
3 – 30<\/td>\n	100 \u2192 70<\/td>\n	0 \u2192 30<\/td>\n<\/tr>\n
30 – 40<\/td>\n	70 \u2192 0<\/td>\n	30 \u2192 100<\/td>\n<\/tr>\n
40 – 50<\/td>\n	0<\/td>\n	100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Flow rate\u00a0 1.2 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 288 nm.<\/p>\n Injection\u00a0 10 \u00b5L.<\/p>\n Identification of impurities\u00a0 Use the chromatogram supplied with nicergoline for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B, C, F and H; use the chromatogram obtained with reference solution (c) to identify the peak due to impurity D; use the chromatogram obtained with reference solution (d) to identify the peak due to impurity I.<\/p>\n Relative retention\u00a0 With reference to nicergoline (retention time = about 34 min): impurity D = about 0.06; impurity C = about 0.1; impurity B = about 0.6; impurity H = about 0.8; impurity A = about 0.96; impurity F = about 1.1; impurity I = about 1.2.<\/p>\n System suitability\u00a0 Reference solution (b):<\/p>\n \u2014 resolution: minimum 2.0 between the peaks due to impurity A and nicergoline.<\/p>\n Calculation of percentage contents:<\/p>\n \u2014 for impurity D, use the concentration of impurity D in reference solution (c);<\/p>\n \u2014 for impurities other than D, use the concentration of nicergoline in reference solution (a).<\/p>\n Limits:<\/p>\n \u2014 impurity B: maximum 0.8 per cent;<\/p>\n \u2014 impurity A: maximum 0.5 per cent;<\/p>\n \u2014 impurity H: maximum 0.3 per cent;<\/p>\n \u2014 impurities C, D, F, I: for each impurity, maximum 0.2 per cent;<\/p>\n \u2014 unspecified impurities: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total: maximum 1.2 per cent;<\/p>\n \u2014 reporting threshold: 0.05 per cent.<\/p>\n Water (2.5.32)<\/p>\n Maximum 0.5 per cent, determined on 0.100 g.<\/p>\n Sulfated ash (2.4.14)<\/p>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n ASSAY<\/h2>\n Dissolve 0.400 g in 50 mL of acetone R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20). Titrate to the 1st point of inflexion. \n1 mL of 0.1 M perchloric acid is equivalent to 48.44 mg of C_{24<\/sub>H_{26<\/sub>BrN_{3<\/sub>O_{3<\/sub>.<\/p>\n}}}} IMPURITIES<\/h2>\n Specified impurities\u00a0 A, B, C, D, F, H, I.<\/em><\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10.<\/em><\/p>\n Control of impurities in substances for pharmaceutical use)\u00a0 E, G, J.<\/em><\/p>\n $\"Nicergoline\"$ <\/p>\n A. [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methyl 5-chloropyridine-3-carboxylate (chloronicergoline),<\/p>\n $\"Nicergoline\"$ <\/p>\n B. [(6aR,9R,10aS)-10a-methoxy-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 5-bromopyridine-3-carboxylate (1-desmethylnicergoline),<\/p>\n $\"Nicergoline\"$ <\/p>\n C. [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methanol,<\/p>\n $\"Nicergoline\"$ <\/p>\n D. 5-bromopyridine-3-carboxylic acid,<\/p>\n $\"Nicergoline\"$ <\/p>\n E. [(6aR,9R,10aS)-10a-hydroxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methyl 5-bromopyridine-3-carboxylate,<\/p>\n $\"Nicergoline\"$ <\/p>\n F. [(6aR,9S,10aS)-10a-methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-\u00a0 yl]methyl 5-bromopyridine-3-carboxylate (isonicergoline),<\/p>\n $\"Nicergoline\"$ <\/p>\n G. [(6aR,9R,10aR)-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl 5- bromopyridine-3-carboxylate,<\/p>\n $\"Nicergoline\"$ <\/p>\n H. [(6aR,9R,10aS)-10a-methoxy-4-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 5-bromopyridine-3-carboxylate (6-desmethylnicergoline),<\/p>\n $\"Nicergoline\"$ <\/p>\n I. [(6aR,6a\u2032R,9R,9\u2032R,10aS,10a\u2032S)-9\u2032-[[[(5-bromopyridin-3-yl)carbonyl]oxy]methyl]-10a,10a\u2032-dimethoxy-7,7\u2032-\u00a0 \u00a0dimethyl-4\u2032,6\u2032,6a,6a\u2032,7,7\u2032,8,8\u2032,9,9\u2032,10,10\u2032,10a,10a\u2032-tetradecahydro-6H-4,5\u2032-biindolo[4,3-fg]quinoline-9-yl]methyl\u00a0 \u00a0 5-bromopyridine-3-carboxylate,<\/p>\n $\"Nicergoline\"$ <\/p>\n J. [(6aR,6a\u2032R,9R,9\u2032R,10aS,10a\u2032S)-9\u2032-[[[(5-bromopyridin-3-yl)carbonyl]oxy]methyl]-10a,10a\u2032-dimethoxy- 4\u2032,7,7\u2032-trimethyl-4\u2032,6\u2032,6a,6a\u2032,7,7\u2032,8,8\u2032,9,9\u2032,10,10\u2032,10a,10a\u2032-tetradecahydro-6H-4,5\u2032-biindolo[4,3-fg]quinoline-9-\u00a0 yl]methyl 5-bromopyridine-3-carboxylate.<\/p>\n \n Ph Eur<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Ergot derivative. Ph Eur DEFINITION [(6aR,9R,10aS)-10a-Methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 \u00a05-bromopyridine-3-carboxylate. Content 99.0 per cent to 101.0 per cent (anhydrous substance). CHARACTERS Appearance Fine to granular, white or yellowish powder. Solubility Practically insoluble in water, freely soluble in methylene chloride, soluble in ethanol (96 per cent). It shows polymorphism…<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-26236","post","type-post","status-publish","format-standard","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=26236"}],"version-history":[{"count":4,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26236\/revisions"}],"predecessor-version":[{"id":26799,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/26236\/revisions\/26799"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=26236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=26236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=26236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

DEFINITION<\/h2>\n[(6aR,9R,10aS)-10a-Methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 \u00a05-bromopyridine-3-carboxylate.<\/p>\nContent<\/strong><\/p>\n99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n

Appearance<\/h3>\nFine to granular, white or yellowish powder.<\/p>\n

Solubility<\/h3>\nPractically insoluble in water, freely soluble in methylene chloride, soluble in ethanol (96 per cent).<\/p>\nIt shows polymorphism (5.9).<\/p>\n

TESTS<\/h2>\n

ASSAY<\/h2>\nDissolve 0.400 g in 50 mL of acetone R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20). Titrate to the 1st point of inflexion.\n1 mL of 0.1 M perchloric acid is equivalent to 48.44 mg of C24<\/sub>H26<\/sub>BrN3<\/sub>O3<\/sub>.<\/p>\n

DEFINITION<\/h2>\n[(6aR,9R,10aS)-10a-Methoxy-4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]methyl\u00a0 \u00a05-bromopyridine-3-carboxylate.<\/p>\n
Content<\/strong><\/p>\n
99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n

Appearance<\/h3>\n
Fine to granular, white or yellowish powder.<\/p>\n

Solubility<\/h3>\n
Practically insoluble in water, freely soluble in methylene chloride, soluble in ethanol (96 per cent).<\/p>\n
It shows polymorphism (5.9).<\/p>\n